X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dishman Pharma with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs PLETHICO PHARMA - Comparison Results

DISHMAN PHARMA    Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA PLETHICO PHARMA DISHMAN PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 25.1 -1.1 - View Chart
P/BV x 3.3 0.0 19,969.5% View Chart
Dividend Yield % 0.7 0.0 -  

Financials

 DISHMAN PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
PLETHICO PHARMA
Mar-14
DISHMAN PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs374395 94.8%   
Low Rs12931 411.8%   
Sales per share (Unadj.) Rs197.8604.4 32.7%  
Earnings per share (Unadj.) Rs21.232.5 65.3%  
Cash flow per share (Unadj.) Rs34.751.3 67.6%  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs179.9473.6 38.0%  
Shares outstanding (eoy) m80.6934.08 236.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x1.30.4 360.8%   
Avg P/E ratio x11.96.6 180.9%  
P/CF ratio (eoy) x7.24.2 174.6%  
Price / Book Value ratio x1.40.5 310.9%  
Dividend payout %9.40-   
Avg Mkt Cap Rs m20,3067,262 279.6%   
No. of employees `0000.8NA-   
Total wages/salary Rs m5,3551,596 335.5%   
Avg. sales/employee Rs Th19,252.7NM-  
Avg. wages/employee Rs Th6,459.5NM-  
Avg. net profit/employee Rs Th2,064.1NM-  
INCOME DATA
Net Sales Rs m15,96120,598 77.5%  
Other income Rs m265386 68.7%   
Total revenues Rs m16,22620,984 77.3%   
Gross profit Rs m4,1032,818 145.6%  
Depreciation Rs m1,091642 169.8%   
Interest Rs m9441,593 59.3%   
Profit before tax Rs m2,334969 240.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m10-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m624-138 -450.6%   
Profit after tax Rs m1,7111,107 154.6%  
Gross profit margin %25.713.7 187.9%  
Effective tax rate %26.7-14.3 -187.0%   
Net profit margin %10.75.4 199.5%  
BALANCE SHEET DATA
Current assets Rs m11,01818,877 58.4%   
Current liabilities Rs m9,51711,896 80.0%   
Net working cap to sales %9.433.9 27.7%  
Current ratio x1.21.6 73.0%  
Inventory Days Days11036 307.5%  
Debtors Days Days35198 17.6%  
Net fixed assets Rs m16,3049,861 165.3%   
Share capital Rs m161341 47.4%   
"Free" reserves Rs m12,90712,331 104.7%   
Net worth Rs m14,51616,139 89.9%   
Long term debt Rs m4,1894,706 89.0%   
Total assets Rs m29,80533,146 89.9%  
Interest coverage x3.51.6 215.9%   
Debt to equity ratio x0.30.3 99.0%  
Sales to assets ratio x0.50.6 86.2%   
Return on assets %8.98.1 109.4%  
Return on equity %11.86.9 171.9%  
Return on capital %17.512.3 142.6%  
Exports to sales %24.821.4 116.0%   
Imports to sales %3.715.2 24.5%   
Exports (fob) Rs m3,9564,402 89.9%   
Imports (cif) Rs m5963,136 19.0%   
Fx inflow Rs m4,9524,402 112.5%   
Fx outflow Rs m6973,184 21.9%   
Net fx Rs m4,2551,219 349.2%   
CASH FLOW
From Operations Rs m2,7862,437 114.3%  
From Investments Rs m-1,529-6,265 24.4%  
From Financial Activity Rs m-9412,490 -37.8%  
Net Cashflow Rs m316-1,337 -23.7%  

Share Holding

Indian Promoters % 61.4 82.7 74.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.7 4.3 86.0%  
FIIs % 12.7 5.5 230.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 7.5 294.7%  
Shareholders   46,261 10,665 433.8%  
Pledged promoter(s) holding % 35.8 85.7 41.7%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   SUVEN LIFE  SHASUN PHARMA  PFIZER  TTK HEALTHCARE  SUN PHARMA  

Compare DISHMAN PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Close at Record Highs; Bank & Realty Stocks Rally(Closing)

After opening the day marginally higher, Indian share markets extended gains in the afternoon session after the government decided to cut tax rates on certain products and services.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA - TTK HEALTHCARE COMPARISON

COMPARE DISHMAN PHARMA WITH

MARKET STATS